In mid-September, Novo Nordisk inked a pair of deals worth a total of more than $1.1 billion in research and development (R&D ...

The healthcare company's pivot into a new set of technologies will have many implications for the stock.

Novo Nordisk CEO grilled over company's pricing for the diabetes drug Ozempic and the weight-loss drug Wegovy.

Novo Nordisk CEO Lars Fruergaard Jørgensen is testifying before the Senate Health, Education, Labor and Pension committee on ...

Pharmaceutical giant Novo Nordisk (NYSE: NVO) is a terrific stock for many reasons. The company continues to deliver ...

A committee report found the weight loss drug is offered for less than $100 in some European countries, compared to monthly ...

German drug and development company Evotec has entered into a technology development partnership with Novo Nordisk to support ...

Weight-loss drugs sell in Europe for a fraction of what they cost in the United States, a pattern that is typical for ...

The CEO of Novo Nordisk wouldn’t commit to lowering the prices of Ozempic and Wegovy during a Senate hearing Tuesday, despite ...

Novo Nordisk CEO explains decision to discontinue the long-acting insulin Levemir. He blamed pharmacy managers and health ...

Novo Nordisk has earnt yet another dressing down from the PMCPA. The U.K. | Novo Nordisk has earnt yet another dressing down ...

During a tense hearing before a Senate committee on Tuesday, Novo Nordisk CEO Lars Fruergaard Jørgensen faced toug ...